Journal
CANCER LETTERS
Volume 290, Issue 2, Pages 192-203Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2009.09.010
Keywords
Trastuzumab; Immunoliposomes; Melittin; Cell lysis; HER2; Anticancer therapy; Breast cancer cells
Categories
Funding
- CGB-ED-SON
- [AGL2007-60778]
Ask authors/readers for more resources
Trastuzumab (Herceptin (TM)) targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-30% of breast and ovarian cancers carrying a bad prognosis. Our purpose was to target HER2-overexpressing human breast cancer cells with pegylated immunoliposomes bearing trastuzumab and containing melittin, which has recently shown anticancer properties. Using a panel of human breast cancer cells with different HER2 expression levels, these immunoliposomes decreased cancer cells viability in a dose-response manner and in correlation to their level of HER2 expression. Specific binding of the immunoliposomes to SKBr3 breast cancer cells was shown by ImageStream-based analysis. The morphological changes observed in the treated cells suggested a cytolytic process. This preclinical approach may suppose an effective strategy for the treatment of HER2-overexpressing tumors, and can support the development of an early phases I-II clinical trial. Trastuzumab resistant breast cancer cells (JIMT-1), can also be targeted using this approach. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available